C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 207/34 (2006.01) A61K 31/40 (2006.01) A61P 9/10 (2006.01) A61P 9/12 (2006.01) A61P 25/00 (2006.01)
Patent
CA 2539454
It is intended to provide a novel preventive for cerebral stroke recurrence and a method of conveniently evaluating a preventive for cerebral stroke recurrence. By using a convenient evaluation method with the use of spontaneously hypertensive rat-stroke prone (SHR-SP) rats having been established by us, it is proved that atorvastatin has effects of preventing cerebral stroke recurrence, relieving nerve symptoms in relapsed cerebral stroke and elevating the survival ratio after the onset of cerebral stroke. That is to say, atorvastatin is useful as a preventive for cerebral stroke recurrence.
L'invention concerne un nouvel agent prophylactique utilisé lors de la répétition d'apoplexies cérébrales, ainsi qu'une méthode d'évaluation appropriée d'un agent prophylactique utilisé lors de répétition d'apoplexies cérébrales. L'utilisation d'une méthode d'évaluation adéquate employant des rats sujets à des apoplexies spontanément hypersensibles permet de démontrer que l'atorvastatine présente des effets de prévention sur la répétition d'apoplexies cérébrales, de soulagement de symptômes nerveux lors d'une apoplexie de rechute et d'augmentation du taux de survie, après l'apparition d'une apoplexie cérébrale. L'atorvastatine est utilisée en tant qu'agent prophylactique destiné à la répétition d'apoplexies cérébrales.
Hayashi Asuka
Sasamata Masao
Suzuki Masanori
Astellas Pharma Inc.
Dennison Associates
LandOfFree
Preventive for cerebral stroke recurrence does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preventive for cerebral stroke recurrence, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preventive for cerebral stroke recurrence will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1610076